Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Corvus Pharmaceuticals reports Q4 loss, highlights CPI-818 potential and challenges

Corvus Pharmaceuticals showcased a mixed financial performance with a focus on managing cash burn rate and extending cash runway.
The company's strength lies in the potential of CPI-818 in various indications and the identification of a patient selection biomarker.
Challenges include cash management, regulatory hurdles in upcoming trials, and the need for clarity on biomarker validation.
Opportunities abound in market expansion, clinical development acceleration, and strategic initiatives for growth and value creation.

Corvus Pharmaceuticals reports Q1 progress with CPI-818 advancements

Corvus Pharmaceuticals reported financial improvements and progress in CPI-818 development.
Partnerships and upcoming trials indicate a promising future for the company.
Challenges lie in addressing analyst queries and ensuring trial success and data presentation.

Corvus Pharmaceuticals reports Q2 progress in cancer drug trials

Corvus Pharmaceuticals reported improved financials with reduced expenses and strategic stock sales, while advancing key drug trials in cancer treatment.
The company's focus on innovative drug development in cancer immunotherapy presents opportunities for growth and partnerships.
Challenges lie in managing expenses, conducting rigorous clinical evaluations, and balancing financial decisions with strategic priorities.

Corvus Pharmaceuticals reports Q3 progress in oncology and immune diseases

Corvus Pharmaceuticals reported a net loss of $6 million in Q3 2023 but showcased progress on soquelitinib and potential in ITK inhibition for immune diseases.
The company's financial overview and upcoming milestones indicate a strategic focus on advancing pipeline candidates and exploring partnerships.
While facing challenges in managing expenses and balancing resources, Corvus Pharmaceuticals has opportunities to drive growth through positive trial results and strategic partnerships.

Corvus Pharmaceuticals advances pipeline with promising therapies and partnerships

Corvus Pharmaceuticals showcased financial improvements and progress in their pipeline programs during Q4 2023 earnings call.
The company's focus on ITK inhibition and orphan drug designation for soquelitinib highlight their commitment to innovative therapies.
While facing cash challenges, Corvus is actively seeking partnerships and advancing trials to capitalize on commercial and medical opportunities.

Corvus Pharmaceuticals reports improved financials and promising clinical advancements

Corvus Pharmaceuticals demonstrated improved financials and strong clinical progress in Q1 2024, supported by recent financing.
The company's focus on Soquelitinib and ciforadenant presents promising opportunities for growth and advancement in the oncology space.
Challenges lie in operational scalability, trial design complexities, and the need for clear patient criteria and efficacy benchmarks.

Corvus Pharmaceuticals reports strong Q2 performance and advances key drugs

Corvus Pharmaceuticals demonstrated financial stability and clinical progress in Q2 2024, with a strong cash position and promising pipeline.
The company's focus on selective ITK inhibition for immune diseases and cancer shows commitment to innovative therapies and addressing unmet medical needs.
While facing challenges in trial expectations and resource allocation, Corvus Pharmaceuticals has opportunities for growth through portfolio diversification and milestone achievements.
Overall, Corvus Pharmaceuticals is well-positioned to capitalize on its strengths, navigate challenges, and seize opportunities in the biopharmaceutical market.

Corvus Pharmaceuticals reports Q3 losses but advances key cancer treatments

Corvus Pharmaceuticals' Q3 performance reflects increased R&D expenses but a secure financial position with available cash and potential additional funds.
The company's strengths lie in its strong pipeline, progress in key trials, and a stable financial runway into 2026 for upcoming milestones.
Challenges include addressing questions on trial specifics, competitive landscape scrutiny, and operational complexities in trial management.
Opportunities exist in advancing innovative treatments, exploring market potential, and addressing immunotherapy resistance in cancer therapy.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks.

Why Investors Are Excited About This New Immunotherapy COVID-19 Study

Shares of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) are advancing strongly Tuesday following an announcement concerning its foray into COVID-19 treatment.

Corvus Skyrockets After Initiating COVID-19 Clinical Trial

Shares of Corvus Pharmaceuticals Inc. CRVS, +77.73% soared 81.2% in trading on Tuesday after the company said it launched an open-label Phase 1 clinical trial testing an experimental monoclonal antibody as a treatment for COVID-19.

Corvus stock jumps on launch of early-stage trial for coronavirus treatment

Approach stimulates immune response by activating B cells to enhance antibody production

Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19

Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders

Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with Ciforadenant

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2020 Results - Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2019 Results - Earnings Call Transcript

Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

BURLINGAME, Calif., Feb.  19, 2020  (GLOBE NEWSWIRE) -- Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, was awarded with the 2020 Drug Hunter Award on February 11, 2020 by the UC Drug Discovery Consortium in a ceremony held at the University of California, San Francisco (UCSF). This annual award and lecture series is sponsored by the UC Drug Discovery Consortium, UCSF Innovation Ventures, the Center for Drug Discovery Innovation, and the law firm of Wilson Sonsini Goodrich & Rosati.

Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium

Corvus Pharmaceuticals: Turnaround In Progress, Multiple Readouts Ahead

Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy

Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting

  SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production

Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q3 2019 Results - Earnings Call Transcript

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results

CRVS stock price has reached cash value, giving no value to its three drugs currently in clinical trials.

Corvus Pharmaceuticals: Bankruptcy Or Blockbuster

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript

The stock has gained 70% during the past month due to significant insider buying.

Corvus Pharmaceuticals: Attractive Entry Level

Shares have lost over a third of their value since my initial article.

Corvus Pharmaceuticals: Insider Buying Ahead Of Potential Turnaround In Second Half Of 2019

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results - Earnings Call Transcript

Today, it is Corvus Pharmaceuticals that is in the spotlight as we take a deeper look at this small cap developmental concern.

News for Corvus Pharmaceuticals Stock (CRVS)